| Literature DB >> 31904350 |
Yuxuan Hu1, Tian Zeng1, Zheng Xiao1, Qihao Hu2, Yukun Li1, Xiongjin Tan3, Haiyan Yue4, Wensong Wang1, Hui Tan5, Juan Zou6.
Abstract
B7 homolog 6 (B7-H6) has been identified as involved in tumorigenesis. Elucidating its role and potential mechanism of action is essential for understanding tumorigenesis and the potential development of an effective clinical strategy. Abnormal overexpression of B7-H6 in various types of tumors was reported to be linked with poor prognosis. B7-H6 suppresses the initiation of the "caspase cascade" and induces anti-apoptosis by STAT3 pathway activation to provoke tumorigenesis. B7-H6 facilitates tumor proliferation and cell cycle progression by regulating apoptosis suppressors. B7-H6 induces cellular cytotoxicity, secretion of TNF-α and IFN-γ and B7-H6-specific BiTE triggers T cells to accelerate tumorigenesis. B7-H6 induces abnormal immunological progression by HER2-scFv mediated ADCC and NKp30 immune escape to promote tumorigenesis. B7-H6 promotes tumorigenesis via apoptosis inhibition, proliferation and immunological progression. B7-H6 may a valuable potential biomarker and therapeutic strategy for diagnostics, prognostics and treatment in cancer.Entities:
Keywords: Apoptotic; B7-H6; Immunological progression; Proliferation; Tumorigenesis
Mesh:
Substances:
Year: 2020 PMID: 31904350 DOI: 10.1016/j.cca.2019.12.030
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786